A few weeks back, when the Biden Administration outlined its much-anticipated American Families Plan, it was notable that the president did not include pharmaceutical price reforms in the proposal. At the time, I argued that even though House Democrats would certainly try to insert their drug legislation (H.R. 3) into the reconciliation package, Biden’s decision […]